KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Total Liabilities: 2018-2025

Historic Total Liabilities for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $168.9 million.

  • Twist Bioscience's Total Liabilities rose 19.25% to $168.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.9 million, marking a year-over-year increase of 19.25%. This contributed to the annual value of $168.9 million for FY2025, which is 19.25% up from last year.
  • Latest data reveals that Twist Bioscience reported Total Liabilities of $168.9 million as of Q3 2025, which was up 2.11% from $165.4 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Total Liabilities registered a high of $172.0 million during Q3 2022, and its lowest value of $6.0 million during Q4 2021.
  • Its 3-year average for Total Liabilities is $152.0 million, with a median of $152.6 million in 2024.
  • In the last 5 years, Twist Bioscience's Total Liabilities plummeted by 90.26% in 2021 and then spiked by 2,627.42% in 2022.
  • Over the past 5 years, Twist Bioscience's Total Liabilities (Quarterly) stood at $6.0 million in 2021, then spiked by 2,627.42% to $163.6 million in 2022, then declined by 12.75% to $142.8 million in 2023, then climbed by 6.91% to $152.6 million in 2024, then climbed by 19.25% to $168.9 million in 2025.
  • Its last three reported values are $168.9 million in Q3 2025, $165.4 million for Q2 2025, and $155.5 million during Q1 2025.